Sagimet Biosciences Announces Completion Of Phase 1 Hepatic Impairment Study With FASN Inhibitor Denifanstat
Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today